Machine Learning with Objective Serum Markers and Algorithmic Deep Learning CT Scan Analysis Predicts Brain Death Due to Trauma and Hypoxia

AUTHORS:
Daniel Rafter, MD[1,4] – danjamesrafter@gmail.com
Brett Sterk[1] - brettsterk@gmail.com
Zhuliu Li[1,2] - lixx3617@umn.edu
Tory Schaaf PhD[1,4]- schaa033@umn.edu
Rui Kuang PhD[2] - kuang@umn.edu
Michael Koller[1] - kolle153@umn.edu
Uzma Samadani MD PhD[1,3,4] * - uzma@samadani.com

*Corresponding Author:
Uzma Samadani MD PhD[1,3,4], 1 Veterans Drive, Dept of Neurosurgery, Minneapolis, MN 55417
uzma@samadani.com 917-388-5740

---

[1] Department of Bioinformatics and Computational Biology, University of Minnesota; 100 Church St S.E., Minneapolis MN 55455

[2] Department of Computer Science and Engineering, University of Minnesota; 100 Church St S.E., Minneapolis MN 55455

[3] Division of Neurosurgery, Minneapolis VA, 1 Veterans Drive, Minneapolis, MN 55417

[4] Neurosurgery, Centracare, 1406 6th Ave N, St Cloud, MN 56303

RUNNING TITLE: Traumatic and hypoxic brain death

ABSTRACT:

Background: Prediction of which traumatic and hypoxic brain injuries will progress to brain death is currently based predominantly on history, physical examination and radiographic findings. We investigated how accurately purely objective measures including three neurologic serum markers and algorithmic CT (computed tomograph) scan analysis can predict brain death and differentiate its etiology.

Methods: This prospective observational study enrolled 51 isolated trauma subjects and 19 clinically brain dead subjects that were further divided by mechanism of injury into high-velocity trauma with presumed diffuse axonal injury, cardiopulmonary/respiratory arrest, and found down groups. Levels of glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and S100 Calcium-Binding Protein B (S100B) were compared, and algorithmic analysis of CT scan imaging was performed using an open-source deep learning software (BLAST-CT).

Findings: The prognostic value of various biomarker combinations in identifying subjects progressing to brain death was assessed using machine learning. Prediction accuracy for GFAP, UCH-L1, and S100B and algorithmic CT analysis in combination to predict brain death from among all other cohorts yielded an area under the receiver operator curve of 0.98 versus all other brain injury subjects. This model was also able to distinguish brain death attributed to cardiopulmonary/respiratory arrest from combined non-trauma controls and diffuse axonal injury with an area under the curve of 0.99.

Interpretation: Serum concentrations of GFAP, UCH-L1, and S100B measured within 32 hours of traumatic and hypoxic brain injury (cardiopulmonary/respiratory arrest) and algorithmic CT analysis have utility in prognosticating brain death and predicting its mechanism of injury as either hypoxic or traumatic/unknown (diffuse axonal injury/found down).

Funding: Abbott Labs and the Minnesota State Office of Higher Education.

Keywords:
- Glial fibrillary acidic protein (GFAP)
- S100 Calcium-Binding Protein B (S100β)
- Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
- Traumatic brain injury (TBI)
- Brain death

INTRODUCTION

As many as half of all trauma patients present with some level of intoxication, and a high percentage have comorbidities which can potentially obfuscate early detection of severe acute injuries. Obtaining a patient's history, physical examination and computed tomograph (CT) are the current gold standard for assessment in the acute phase of brain injury (Greer et al., 2020).

The history however, is sometimes unavailable due to patient factors or unreliable due to
clinician bias. The physical examination can be confounded by multiple factors, and the
radiologist interpretation of CT scan is not quantifiable or standardized. Thus there may be
variability in patient outcomes as predicted by these subjective measures (Lingsma et al., 2010).

Severe brain injury is a leading cause of disability worldwide (Faul and Coronado, 2015) and its
mechanistic heterogeneity has proven to be a barrier for advancing both diagnostic and
prognostic technologies. It is estimated that 39% of patients with a severe traumatic or
atraumatic brain injury (Rosenfeld et al., 2012) progress to brain death within their initial
admission. The mechanistic heterogeneity of severe brain injury implies that some injuries may
potentially be more reversible than others, but the point at which injury becomes irreversible, and
differentiating among the pathologies to identify any reversible processes is currently
challenging. Two mechanistically dichotomous pathologies that may potentially advance to brain
death are traumatic diffuse axonal injury and atraumatic anoxic or hypoxic brain injury. Severe
edema, hypoxia, or infarction are associated with these pathologies and contribute to brain death,
resultant edema, loss of blod flow and neuronal death. A diffuse axonal injury results from high
velocity shearing forces at the gray-white matter interface, particularly in the corpus callosum
and brainstem (Mesfin et al., 2020). Anoxia results after as little as 20 seconds of circulatory
arrest depletes neuronal oxygen stores resulting in loss of consciousness. Continued insufficient
circulatory support for 10 minutes is generally lethal. Radiographic signs of hypoxic injury are
frequently undetectable in the acute setting, and sequelae of structural disruption including
global edema and diffusion weighted changes may not be evident until days after the original
insult making accurate prognostication difficult (Nguyen et al., 2018). As such, there is a strong
need for improved prognostic measures of brain death in diffuse axonal injuries, anoxic brain
injury due to cardiac or respiratory arrest, and brain injury of unknown origin in order to make
informed clinical decisions about withdrawing life support, avoiding futile interventions,
allocating resources and monitoring progression and therapeutic responses (Wang et al., 2018).

Serum biomarkers offer potential to aid in objective measurement and prognostication of brain
injury (Wang et al., 2018), and have been examined in various brain injury cohorts including
brain death (Mahan et al., 2019). In particular, glial fibrillary acidic protein (GFAP), the
predominant filament protein in the astrocytic skeleton has demonstrated potential as a marker of
astrocytic injury (Mahan et al., 2019), and is markedly upregulated during astrogliosis, a process
in which astrocytes increase in size and number in response to traumatic and anoxic injury
(Egea-Guerrero et al., 2013). Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is a neuron-
specific protein, known for its role in the addition and removal of ubiquitin from proteins (Papa
et al., 2016). Much like GFAP, UCH-L1 is elevated in the serum following a traumatic brain
injury and is predictive of injury severity and presence of intracranial lesions on head CT (Diaz-
Arrastia et al., 2014). S100B is a well-studied biomarker that functions in astrocytes as a major
homeostatic calcium-binding protein and is released into the serum after brain injury (Rodriguez-
Rodriguez et al., 2016). One study investigated S100B in both severe traumatic brain injured and
cardiac arrest patients, finding that concentrations measured at 12 hours post-admission were
comparable between traumatic brain injured and cardiac arrest groups, as well as predictive of
unfavorable neurologic outcome (Mussack et al., 2002).

The aim of this study is to explore the potential role of serum biomarkers and algorithmic open-
source deep-learning CT scan analysis (Mahan et al., 2019) in predicting brain death in both non-

traumatic and traumatic brain injuries. Our goal is to use machine learning to develop a brain
injury stratification model based on algorithmic CT scan analysis and concentrations of three
serum markers GFAP, UCH-L1, and S100B taken within 32 hours of hospital admission. The 32
hour time point was chosen based on previous work demonstrating that serum biomarker
concentrations during this time frame can be used to accurately predict CT positive and CT
negative scans from patients with traumatic brain injuries (Mahan et al., 2019). This model will
predict those at risk for brain death from among patients who suffered a traumatic or atraumatic
brain injury. Evaluation of these objective measures may be useful in classifying the
pathophysiology of injury as due to cardiac/respiratory arrest (CA/RA), unknown etiology/found
down (FD), or diffuse axonal injury (DAI).

MATERIALS & METHODS

Study Design

Institutional Review Board approval (HSR #15-4079) was obtained for prospective enrollment of
patients who presented to the emergency department of a level-1 trauma center between May
2016 and April 2017. Subjects were consented if they were able to pass the Galveston
Orientation and Amnesia Test (GOAT) and met criteria for providing informed consent. If they
were not able to provide informed consent initially, a legally authorized representative was
consented and the subject was reconsented once able. Only in situations where the subject
expired in the hospital and family or a legally authorized representative could not be contacted
was informed consent waived. Informed consent or waiver of consent was obtained prior to data
inclusion. Specific information regarding study setting, population, determination of key
outcome measures, neuroimaging techniques, classification, blood collection and processing, and
machine learning are included in the supplemental materials.

Machine Learning

Support Vector Machine (SVM) (Corinna Cortes, 1995) was utilized for the classification of the
patient samples in our prediction tasks. Among the supervised learning methods, SVM
generalizes well on new test data, and the decision function of SVM is simply defined by a
subset of training samples without requiring training with big data (Supplemental Methods).
143
Leave-one-out cross-validation and parameter tuning
We perform leave-one-out cross-validation to evaluate the prediction performance of SVM. In
the evaluation, we hold out one sample at a time as the test data and treat the rest samples as
training data to obtain the SVM model for classifying the held-out sample in the test data. We
repeat the procedure on every sample and report the overall test accuracy in Table 3 and Table 4.
The parameters σ and $\frac{1}{2N\lambda}$ are chosen from (0.1, 0.5, 1, 5, 10) by grid searching.

Measurements of the Prediction Accuracy

We comprehensively measured the classification accuracy using the Area Under the receiver
operator Curve (AUC), and Average Precision (AP) (Fawcett, 2006; Zhang E., 2009). Denoting
the number of true positives, true negatives, false positives and false negatives as TP, TN, FP,

and FN respectively, the true positive rate (TPR), false positive rate (FPR) and precision (PR) are
defined as:

$$TPR = \frac{TP}{TP + FN}, \quad FPR = \frac{FP}{FP + TN}, \quad PR = \frac{TP}{TP + FP}$$

● Area Under the receiver operator Curve (AUC) measures the area under the receiver
operating characteristic curve which plots the true positive rate (TPR) and false positive rate
(FPR) at different classification thresholds. Thus, the AUC represents the probability that a
randomly chosen positive sample receives a higher score than a randomly chosen negative
sample.

● Precision@K measures the fraction of detected positive samples among the top-K
predictions of the machine learning model, i.e., if there are N true positives among the top-K
predictions then Precision@K is defined as

$$\text{Precision@}K = \frac{N}{K}$$

166 ● Average Precision (AP) measures the mean of the precision values after each positive
167 sample is detected, which is defined as

$$AP = \frac{\sum_R \text{Precision@}R}{P}$$

169 where R is the rank of each positive sample, and P is the total number of positive samples in the
170 data. A high average precision score indicates that the SVM classifier can correctly identify most
171 true positive samples without making too many false positives.

RESULTS

779 brain injury subjects and healthy controls enrolled during the study period and 331 were
determined to have at least one valid biomarker result within 32 hours of injury. Of these eligible
subjects, 21 expired during their initial admission with a final diagnosis of brain death. One
subject was excluded due to invalid results on all three of the biomarkers of interest, GFAP,
UCH-L1, and S100b, and another who suffered a gunshot wound to the head was excluded on
the basis of penetrating brain injury. The remaining 19 brain death subjects (13 male, 6 female),
had a mean (SD) age of 58.6 (17.6) with a range of 24-87. For comparative purposes, 51 isolated
traumatic brain injury subjects with at least one valid biomarker result within 32 hours of injury
were identified and further categorized as CT-positive (CTp) and CT-negative (CT-n) cohorts
using the Marshall Classification (Marshall et al., 1992). 21 CTp subjects (15 male, 6 female)
had a mean (SD) age of 56.2 (16.8) with a range of 31-85 and 30 CTn subjects (21 male, 9
female) had a mean (SD) age of 50.4 (25.5) with a range of 4-95. 15 non-trauma subjects that
survived their initial admission (8 male, 7 female) had a mean (SD) age of 53.8 (15.4) with a
range of 18-86. Additionally, 41 healthy control subjects (CTL) (11 male, 30 female) had a mean
(SD) age of 37.1 (14.0) with a range of 16-65. Characteristics of all cohorts are displayed in
Table 1.

The highest GCS scores were observed in the CTn group with 93% having a high GCS (13-15,
N=28), while 95% (N=18) of the BD subjects had low GCS scores (8 or less) at the time of
arrival to the emergency department. 62% (N=13) of CTp subjects had a high GCS (13-15) while
the non trauma group had only 40% (N=6) with a high GCS and the majority (53%, N=8) had a
low GCS. Loss of consciousness duration showed a similar trend with 50% (N=15) of CTn
subjects having no loss of consciousness, while only 33% (N=5) of NT subjects had no LOC.
29% (N=6) of CTp had a loss of consciousness duration of 0 - 30 minutes, while most (74%,
N=14) BD patients experienced greater than 24 hours of loss of consciousness prior to brain
death diagnosis. Unknown loss of consciousness duration (unable to be obtained) remained a
significant portion of all groups with 48% (N=10) of CTp and 53% (N=8) of non trauma patients
having unknown loss of consciousness duration. A head CT was obtained for all brain injury
patients except for one patient, who was in the brain death cohort. Mean (range) Marshall score
for groups were 3.1 (1 - 6) for brain death subjects, 1 (1-1) for CTn, 2.14 (2 - 4) for CTp, and
2.47 (1 - 6) for the non trauma group. For the brain death subjects, the most prevalent mechanism
of injury was found down (FD, 53%, N=10), followed by cardio-pulmonary arrest (CA/RA,
37%, N=7) and high velocity trauma/presumed diffuse axonal injury (11%, N=2).

Measures of central tendency (mean, median), dispersion (standard deviation (SD), interquartile
range [25-75%] (IQR)) for the time differences from reported time of injury to blood sample
collection for each of the four subject groups were comparable. The mean (SD | median | IQR)
time of injury to blood draw was 720.5 minutes (543.4 | 562 | 270-1,227) for brain death, 671.8
minutes (529.9 | 465 | 234-1,284) for CTp, 581.7 minutes (598.4 | 295 | 140.75-1,214.25) for
CTn, and 723.6 minutes (624.76 | 430 | 200-1,348) for non trauma. Within the brain death
cohort, the mean (SD | median | IQR) time of injury to blood sample collection for each
mechanism of injury was 8631 minutes (547.6 | 821 | 312-1,373) for FD, 505.1 minutes (501.8 |
320 | 205-525) for CA/RA, and 911.2 minutes (507.1 | 1,053 | 930-1,172) for diffuse axonal
injury.

The number of samples and mean serum biomarker concentration for each patient cohort are
reported in table 3. There were less patients overall for S100B samples. Serum concentrations of
GFAP and UCH-L1 were found to be significantly different for each cohort. Detailed
information about the total number of UCH-L1, GFAP, and S100B samples with detailed
statistics and pg/mL concentrations for each patient cohort can be found in supplemental
materials and figure 2. GFAP and UCH-L1 log concentrations were combined and evaluated as
predictors of brain death using machine learning with Support Vector Machine (SVM) as shown
in Table 4. Log-transformed concentrations of GFAP and UCH-L1 for each sample within the
four subject groups and controls were plotted and shown in Figure 2 with contour lines. The area
under the curve (AUC) for the brain death cohort was 0.95 (average precision of 0.85) compared
to all others (CTL, non trauma, CTn, CTp); 0.94 [average precision of 0.85]) compared to all
brain injury groups (non trauma, CTn, CTp); and 0.91 [average precision of 0.88]) compared to
non trauma and CTp (Table 4). When the brain death group is delineated by mechanism of
injury, as plotted in Figure 2, combinations of GFAP and UCH-L1 can predict brain death via
CA/RA compared to brain death by FD or diffuse axonal injury with an AUC of 0.96 (average
precision of 0.96, Table 4). The inclusion of the automated CT analysis (Blast-CT) into the
multimodal algorithm improved the ability to differentiate brain death due to cardiac arrest from
found down and diffuse axonal injury etiology.

The ability of the combination of all 3 biomarkers to predict brain death was also assessed. Log-
transformed concentrations of UCH-L1, GFAP, and S100B for each sample within the four
subject groups and controls are shown in Figure 2. The AUC for UCH-L1, GFAP, and S100B
combination in brain death was 0.98 (average precision of 0.92) compared to all others (CTL,
non trauma, CTn, CTp); 0.96 (average precision of 0.91) compared to all brain injury groups
(non trauma, CTn, CTp); and 0.93 (average precision of 0.91) when compared to non trauma and
CTp (Table 5). The three biomarker combination was also able to distinguish CA/RA brain death
from combined non trauma and diffuse axonal injury brain death with an AUC of 0.98 (average
precision of 0.97, Table 4, Figure 2). Validation of the machine learning algorithm was assessed
using two different measures of area under the curve and average precision which as shown in
Table 4 and 5. The inclusion of the automated CT analysis (Blast-CT) into the multimodal
algorithm with all three serum biomarker did not improve the ability to differentiate brain death
due to cardiac arrest from found down and diffuse axonal injury etiology.

DISCUSSION

Brain injury is unlike injury to other organ systems in the body, because there are a lack of
objective measures to classify the nature and severity of the problem. Without such measures, it
is difficult to test therapeutics and prognosticate accurately (Rodriguez-Rodriguez et al., 2016).
The aim of this study was to determine whether or not brain death could be predicted by a
machine learning analysis of objective measures including algorithmic CT scan analysis and
serum levels of GFAP, UCH-L1 and S100B following traumatic and atraumatic head injury. Our
current ability to prognosticate neurologic outcome following cardiac arrest is limited and,
similarly, accurate prognostication following a traumatic brain injury is difficult (Rodriguez-
Rodriguez et al., 2016). Serum biomarkers have been investigated as a means to diagnose, risk-
stratify and predict unfavorable outcome in both traumatic and non-traumatic brain injury
patients, but few studies have used clinically-confirmed brain death as the main outcome
measure (Egea-Guerrero et al., 2013; Wang et al., 2018). In the present study, biomarker
concentrations within the first 32 hours post injury were evaluated for their ability to distinguish
patients who eventually suffered brain death from those who survived. Further stratification in
future work may enable even more precise prediction of deficit versus permanent disability
(Geocadin et al., 2019). Biomarkers may identify patients for whom continuation of intensive
life-sustaining efforts may prove futile, or conversely, identify patients for whom early induction
of intensive therapy may provide maximal utility and offer improved outcomes (Okonkwo et al.,
2020).

The findings of this study indicate that serum concentrations of three markers and CT scan
analyses are different in subjects who died of brain death as a result of traumatic or atraumatic
brain injury when compared to those who survived a traumatic brain injury with positive head
CT, traumatic brain injury with negative head CT, non-traumatic brain injury, and controls
(Figure 1). These findings are consistent with numerous studies that have found a strong
association between GFAP and UCH-L1 levels in the acute post- traumatic brain injury setting
and unfavorable outcome including death as measured by the Glasgow Outcome Scale (GOS) or
extended GOS (GOSE) at 6 months post-injury (Di Battista et al., 2015; Mondello et al., 2016),
as well as survival vs non-survival (Brophy et al., 2011; Mondello et al., 2012). Moreover,
GFAP elevations have previously been shown to predict neurologic outcome following cardiac
arrest (Larsson et al., 2014; Helwig et al., 2017). This study is among the first to demonstrate the

utility of GFAP and UCH-L1 in predicting clinical brain death as opposed to simply predicting
mortality.

Combinations of CT analysis plus two biomarkers (GFAP and UCH-L1, Table 4) and three
biomarkers (GFAP, UCH-L1 and S100B, Table 5) were highly predictive of brain death with
AUCs greater than 0.90 when compared to all others (CTL, non trauma, CTn, CTp; AUC = 0.95
and 0.98, AP = 0.85 and 0.92, respectively), brain injury groups (non trauma, CTn, CTp; AUC =
0.94 and 0.96, AP = 0.85 and 0.91, respectively), and non trauma and CTp (AUC = 0.91 and
0.93, AP = 0.88 and 0.91, respectively) (Table 4 & 5). These AUC values were supported by
high average precision (AP) for all comparisons. The inclusion of S100B to the model increased
the AUC slightly over the two biomarker combination, indicating that S100B adds predictive
value, despite the lack of significant difference in mean concentration compared to individual
brain injury groups. As expected, the AUC is highest when compared to all others, which
includes both brain injury groups and healthy controls. The AUC remains high even when
comparing brain death only to non trauma and CTp, which is the most clinically relevant
distinction.

Among our 19 brain death subjects, two suffered a high velocity traumatic brain injury consistent
with diffuse axonal injury, seven suffered CA/RA and the remaining 10 were found down with
unclear or mixed etiology brain injuries. Interestingly, our models with two and three biomarker
combinations can distinguish between patients who suffered brain death via cardiac arrest (CA)
as compared to a combined cohort of brain death from unknown/found down injury and diffuse
axonal injury with an AUC of 0.96 and 0.98, respectively (Figure 2, Table 4). Of note, this AUC
is higher than when comparing brain death as a whole to all others (CTL, non trauma, CTn, CTp;
3 biomarker AUC = 0.95) when only GFAP and UCH-L1 are used to predict brain death.
Inclusion of the automated CT analysis improved the etiology classification of brain death
subjects from AUC of 0.96 to 0.99. Blast-CT aided in classification and validation of the serum
biomarker algorithm. It did not improve the prediction accuracy when all three serum biomarkers
were included. Expanding our analysis with larger and more diverse datasets may help
differentiate how the inclusion of lesion volume and type could be beneficial in a multimodal
biomarker model.

As observed in Figure 2B, the profile of three serum markers clearly distinguish the brain death
cohort from all other subjects. Figure 2D demonstrates that the CT positive cohort has a larger
range of concentrations but is distinguishable between brain death and non trauma cohorts.
Further, Figure 2F depicts a clear separation of brain death patients who suffered cardiac or
respiratory arrest as compared to those found down with unknown injury and diffuse axonal
injury. Our model represents a novel method to differentiate presumed diffuse axonal injury and
FD patients from those who suffered cardiac or respiratory arrest (CA/RA), which is of particular
importance in situations when the underlying neural insult is unknown or ambiguous. We
hypothesize that the observed differences are a result of the dichotomous pathophysiology
between traumatic and anoxic brain injuries. By comparing mechanism of injury within the brain
death group, we avoid some of the variability in severity that was observed within the brain
injury (CTp, CTn, and non trauma) cohorts. There are several limitations to this study, and the
first of these is that the dataset consists of a relatively small number of patients. While the
number appeared to be sufficient to develop the machine learning algorithm (table 4 and 5), it
was insufficient to enable analysis on a validation set of data. We propose future work in which

the model is tested on larger data sets such as that from the transforming research and clinical
knowledge in traumatic brain injury initiative (TRACK-TBI) (Yue et al., 2013) or (CENTRE
TBI) (Maas et al., 2015) datasets.

An additional caveat is that while objective measures have the potential to reduce biases in care,
they need to be demonstrated to not perpetuate or exacerbate those biases. Automated analysis
of CT scans is likely to be objective regardless of patient's race, sex, gender, culture, education
level or financial status, but whether or not a CT scan is obtained in the first place is almost
certainly a function of these and other biases. Serum markers do show differences between
races, with S100B having the most marked differences. Additional study will be needed to
validate the use of serum markers for prognostication and classification of brain injury in diverse
populations. And again, the decision to obtain serum markers in the first place remains a
function of many factors potentially subject to bias.

We conclude that algorithmic CT analysis and serum levels of GFAP, UCH-L1 and S100B
drawn within 32 hours post traumatic or non-traumatic brain injury can accurately identify
patients who are at significant risk of developing brain death, highlighting the potential utility of
our model to inform a challenging prognosis. Furthermore, these levels can also categorize brain
death subjects by mechanism of injury into either cardiac/respiratory arrest or diffuse axonal
injury. Classifying the nature of injury may be a helpful first step toward development of
therapeutics to treat the consequences of injury.

CONFLICT OF INTEREST STATEMENT
341

Dr. Uzma Samadani reports receiving lecture fees from Abbott; the American Association of
Neuroscience Nurses; Cottage Health; Google Inc.; Integra Corp; Medtronic Corp; National
Neurotrauma Society; Minnesota, Texas, Louisiana, and Wisconsin Coaches Associations; and
the National Football League and USA Football. She also reports receiving grant support from
the State of Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program
administered by the Minnesota Office of Higher Education, Veterans Administration, Abbott
Laboratories, Medtronic, and Integra. Finally, she reports serving as an unaffiliated neurotrauma
consultant to the National Football League for five games during each of the 2015–2018 football
seasons.

351
FUNDING

This study was funded by Abbott Labs and the Minnesota State Office of Higher Education
Project Number 176016. Neither played a role in generation of the manuscript.

ETHICS STATEMENT

This study involving human participants were received and approved by the Human Subjects
Research Committee and Institutional Review Board. The participants provided their informed
written consent to participate in the clinical trial.

DATA AVAILABILITY
360

361   Data will be made available upon reasonable request.
362
363   **AUTHOR CONTRIBUTIONS**
364
365   US provided all oversight for the study. DR, RK, and US designed the study. ZL, BS, DR, BS,
366   and TS were involved in data collection, data analysis, and manuscript writing. RK was involved
367   in investigation and supervision of data analysis. All authors contributed to and approved the
368   final manuscript.
369
370
371   **ACKNOWLEDGMENTS**
372
373   We would like to thank the patients and controls who participated in the study, as well as the
374   Minnesota Office of Higher Education and Abbott Labs for providing funding and resources for
375   these studies.
376
377   **CONTRIBUTION TO THE FIELD STATEMENT**
378
Assessment of the severity of brain injury is currently performed clinically and based on history
and physical examination, along with radiologist interpretation of a CT scan. Such assessments
are confounded by intoxicants, comorbidities and variability in clinical examination skills, along
with examiner bias. Serum markers have recently been shown to predict a positive head CT scan
and correlate with severity of brain injury. Algorithmic CT scan analysis demonstrates
correlation with radiologist interpretation of scans. To date, no one has investigated whether
these objective measures can predict brain death or determine its etiology. S100B, UCH-L1 and
GFAP serum concentrations were collected within 32 hours following injury, in combination
with algorithmic CT scan analysis, can be used to predict brain death in a group of trauma
patients and classify its etiology in a binary fashion. This study represents an important addition
to the literature because objective measures, if they can be demonstrated to be free of bias, have
the potential to increase efficiency, reduce cost and reduce subjective influences in care of brain
injured patients. Advances in the rapid classification and stratification of brain injury will
ultimately enable testing and development of point of care therapeutics and improve patient
outcomes

FIGURE LEGENDS:

Figure 1: Boxplots of Log Concentrations of GFAP, UCH-L1 and S100B for Subject Groups and
Controls. Concentrations of biomarkers are in picograms per milliliter (pg/mL). Values were log-
transformed prior to plotting. Gray represents controls, red represents non-trauma, green represents CT-
negative traumatic brain injury, yellow represents CT-positive traumatic brain injury, and blue represents
brain death.

[A] GFAP

[B] UCH-L1

[C] S100B

Figure 2: Contour and 3D scatterplots of Log Concentrations (pg/mL) of GFAP, UCH-L1, and S100b for
comparison groups.

[A] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death (BD) subjects, brain
injury (BI) subjects which includes CT positive traumatic brain injury, CT negative traumatic brain
injury, and non-trauma, and control (CTL) subjects.

[B] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for BD, BI, and CTL subjects.

[C] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death (BD) subjects, non-
trauma (NT) cohort from BI subjects which includes spontaneous intraparenchymal hemorrhages and
hypoxic injury, and CT positive traumatic brain injury (CTp) subjects.

[D] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for BD, NT, and CTp subjects.

[E] Contour scatterplot of log UCH-L1 and GFAP concentrations for brain death cohorts:
cardiopulmonary arrest (CA/RA), diffuse axonal injury (DAI), and found down (FD) subjects.

[F] 3D scatterplot of log S100b, UCH-L1, and GFAP concentrations for CA/RA, DAI, and FD subjects.

REFERENCES:
417
418

Brophy, G.M., Mondello, S., Papa, L., Robicsek, S.A., Gabrielli, A., Tepas, J., 3rd, et al. (2011).
Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic
brain injury patient biofluids. *J Neurotrauma* 28(6), 861-870. doi:
10.1089/neu.2010.1564.
Corinna Cortes, V.V. (1995). Support-vector networks. *Machine Learning* (20), 273-297.
Di Battista, A.P., Buonora, J.E., Rhind, S.G., Hutchison, M.G., Baker, A.J., Rizoli, S.B., et al.
(2015). Blood Biomarkers in Moderate-To-Severe Traumatic Brain Injury: Potential Utility
of a Multi-Marker Approach in Characterizing Outcome. *Front Neurol* 6, 110. doi:
10.3389/fneur.2015.00110.
Diaz-Arrastia, R., Wang, K.K., Papa, L., Sorani, M.D., Yue, J.K., Puccio, A.M., et al. (2014).
Acute biomarkers of traumatic brain injury: relationship between plasma levels of
ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. *J Neurotrauma* 31(1),
19-25. doi: 10.1089/neu.2013.3040.
Egea-Guerrero, J.J., Murillo-Cabezas, F., Gordillo-Escobar, E., Rodriguez-Rodriguez, A.,
Enamorado-Enamorado, J., Revuelto-Rey, J., et al. (2013). S100B protein may detect
brain death development after severe traumatic brain injury. *J Neurotrauma* 30(20),
1762-1769. doi: 10.1089/neu.2012.2606.
Faul, M., and Coronado, V. (2015). Epidemiology of traumatic brain injury. *Handb Clin Neurol*
127, 3-13. doi: 10.1016/B978-0-444-52892-6.00001-5.
Fawcett, T. (2006). An introduction to ROC analysis. *Pattern recognition letters.* 27(8), 861-874.
Geocadin, R.G., Callaway, C.W., Fink, E.L., Golan, E., Greer, D.M., Ko, N.U., et al. (2019).
Standards for Studies of Neurological Prognostication in Comatose Survivors of Cardiac
Arrest: A Scientific Statement From the American Heart Association. *Circulation* 140(9),
e517-e542. doi: 10.1161/CIR.0000000000000702.

Greer, D.M., Shemie, S.D., Lewis, A., Torrance, S., Varelas, P., Goldenberg, F.D., et al. (2020).
Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death
Project. *JAMA* 324(11), 1078-1097. doi: 10.1001/jama.2020.11586.
Helwig, K., Seeger, F., Holschermann, H., Lischke, V., Gerriets, T., Niessner, M., et al. (2017).
Elevated Serum Glial Fibrillary Acidic Protein (GFAP) is Associated with Poor Functional
Outcome After Cardiopulmonary Resuscitation. *Neurocrit Care* 27(1), 68-74. doi:
10.1007/s12028-016-0371-6.
Larsson, I.M., Wallin, E., Kristofferzon, M.L., Niessner, M., Zetterberg, H., and Rubertsson, S.
(2014). Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting
neurological outcome. *Resuscitation* 85(12), 1654-1661. doi:
10.1016/j.resuscitation.2014.09.007.
Lingsma, H.F., Roozenbeek, B., Steyerberg, E.W., Murray, G.D., and Maas, A.I. (2010). Early
prognosis in traumatic brain injury: from prophecies to predictions. *Lancet Neurol* 9(5),
543-554. doi: 10.1016/S1474-4422(10)70065-X.
Maas, A.I., Menon, D.K., Steyerberg, E.W., Citerio, G., Lecky, F., Manley, G.T., et al. (2015).
Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury
(CENTER-TBI): a prospective longitudinal observational study. *Neurosurgery* 76(1), 67-
80. doi: 10.1227/NEU.0000000000000575.
Mahan, M.Y., Thorpe, M., Ahmadi, A., Abdallah, T., Casey, H., Sturtevant, D., et al. (2019). Glial
Fibrillary Acidic Protein (GFAP) Outperforms S100 Calcium-Binding Protein B (S100B)
and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as Predictor for Positive Computed
Tomography of the Head in Trauma Subjects. *World neurosurgery* 128, e434-e444. doi:
10.1016/j.wneu.2019.04.170.
Marshall, L.F., Marshall, S.B., Klauber, M.R., Van Berkum Clark, M., Eisenberg, H., Jane, J.A.,
et al. (1992). The diagnosis of head injury requires a classification based on computed
axial tomography. *J Neurotrauma* 9 Suppl 1, S287-292.
Mesfin, F.B., Gupta, N., Hays Shapshak, A., and Taylor, R.S. (2020). "Diffuse Axonal Injury," in
StatPearls. (Treasure Island (FL)).
Mondello, S., Kobeissy, F., Vestri, A., Hayes, R.L., Kochanek, P.M., and Berger, R.P. (2016).
Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic
Protein after Pediatric Traumatic Brain Injury. *Scientific reports* 6, 28203. doi:
10.1038/srep28203.
Mondello, S., Linnet, A., Buki, A., Robicsek, S., Gabrielli, A., Tepas, J., et al. (2012). Clinical
utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe
traumatic brain injury. *Neurosurgery* 70(3), 666-675. doi:
10.1227/NEU.0b013e318236a809.
Mussack, T., Biberthaler, P., Kanz, K.G., Wiedemann, E., Gippner-Steppert, C., Mutschler, W.,
et al. (2002). Serum S-100B and interleukin-8 as predictive markers for comparative
neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain
injury. *Crit Care Med* 30(12), 2669-2674. doi: 10.1097/00003246-200212000-00010.
Nguyen, T.V., Hayes, M., Zbesko, J.C., Frye, J.B., Congrove, N.R., Belichenko, N.P., et al.
(2018). Alzheimer's associated amyloid and tau deposition co-localizes with a
homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia.
Acta Neuropathol Commun 6(1), 100. doi: 10.1186/s40478-018-0603-4.
Okonkwo, D.O., Puffer, R.C., Puccio, A.M., Yuh, E.L., Yue, J.K., Diaz-Arrastia, R., et al. (2020).
Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus
S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. *J
Neurotrauma* 37(23), 2460-2467. doi: 10.1089/neu.2020.7140.
Papa, L., Brophy, G.M., Welch, R.D., Lewis, L.M., Braga, C.F., Tan, C.N., et al. (2016). Time
Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and

UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. *JAMA neurology* 73(5)**,** 551-560. doi: 10.1001/jamaneurol.2016.0039.

Rodriguez-Rodriguez, A., Egea-Guerrero, J.J., Gordillo-Escobar, E., Enamorado-Enamorado, J., Hernandez-Garcia, C., Ruiz de Azua-Lopez, Z., et al. (2016). S100B and Neuron-Specific Enolase as mortality predictors in patients with severe traumatic brain injury. *Neurol Res* 38(2)**,** 130-137. doi: 10.1080/01616412.2016.1144410.

Rosenfeld, J.V., Maas, A.I., Bragge, P., Morganti-Kossmann, M.C., Manley, G.T., and Gruen, R.L. (2012). Early management of severe traumatic brain injury. *Lancet* 380(9847)**,** 1088-1098. doi: 10.1016/S0140-6736(12)60864-2.

Wang, K.K., Yang, Z., Zhu, T., Shi, Y., Rubenstein, R., Tyndall, J.A., et al. (2018). An update on diagnostic and prognostic biomarkers for traumatic brain injury. *Expert Rev Mol Diagn* 18(2)**,** 165-180. doi: 10.1080/14737159.2018.1428089.

Yue, J.K., Vassar, M.J., Lingsma, H.F., Cooper, S.R., Okonkwo, D.O., Valadka, A.B., et al. (2013). Transforming research and clinical knowledge in traumatic brain injury pilot: multicenter implementation of the common data elements for traumatic brain injury. *J Neurotrauma* 30(22)**,** 1831-1844. doi: 10.1089/neu.2013.2970.

Zhang E., Z.Y. (2009). Average Precision. *Encyclopedia of Database Systems. Springer, Boston, MA*.

541 **TABLES**

542 **Table 1 - Study demographics cohorts**

Data Point		Brain Death	CT (+) TBI	CT (-) TBI	Non-Trauma	Controls
N		19	21	30	15	41
Male \ Female		13 : 6	15 : 6	21 : 9	8 : 7	11 : 30
		P-value (chi squared)	084	0·004	0·029	0·00000000001
Age (mean, range)		58·6, 24 - 87	56·2, 31 - 85	50·4, 4 - 95	53·8, 18 - 86	37·1, 16 - 65
		P-value	0·69	0·23	0·42	0·000004
LOC	None	1 (5%)	3 (14%)	15 (50%)	5 (33%)	41
	0 - 30 mins	2 (11%)	6 (29%)	8 (27%)	1 (7%)	-
	30 mins - 24 hrs	0 (0%)	2 (10%)	0 (0%)	1 (7%)	-
	> 24 hrs	14 (74%)	0 (0%)	0 (0%)	0 (0%)	-
	Unknown	2 (11%)	10 (48%)	7 (23%)	8 (53%)	-
GCS	13 - 15	1 (5%)	13 (62%)	28 (93%)	6 (40%)	41
	9 -12	0 (0%)	3 (14%)	1 (3%)	1 (7%)	-
	8 or less	18 (95%)	5 (24%)	1 (3%)	8 (53%)	-
Percent with clinical CT		95%	100%	100%	100%	0 %
Marshall Score (mean, range)		3·1, 1 - 6	2·14, 2 - 4	1	2·47, 1 - 6	-
Length of Stay	0 - 48 hrs	5	7	27	0	-
	49 - 96 hrs	4	5	2	3	-
	> 96 hrs	10	9	1	12	-
Discharge Location	Home	0	13	29	4	-
	Rehab	0	8	1	11	-
	Morgue	19	0	0	0	-

543   Table 1 footnote: Loss of consciousness (LOC), Glasgow Coma Scale (GSC), and computed tomography
544   (CT).

Table 2 – Concentrations (pg/mL) of GFAP, UCH-L1, and S100B from brain death cohorts shown at each

blood draw time point

Subject	Mechanism of Injury	Age, Sex	GCS	Marshall Score	GFAP			UCH-L1			S100B		
					0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury	0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury	0 hours (admission)	1 - 8 hours post injury	12 - 32 hours post injury
CA/RA-1	Cardiac arrest	50s, M	3T	n/a	15·4	27·0	946·7	4,163·6	4,486·1	2,844·6	1,030·0	52·0	41·0
CA/RA-2	Cardiac arrest	80s, M	3T	1	17·4	30·8	-	4,566·7	11,416·8	-	-	-	-
CA/RA-3	Cardiac arrest	20s, F	3T	3	37·7	78·5	-	1,067·7	561·7	-	55·0	53·0	-
CA/RA-4	Cardiac arrest	40s, M	3T	1	53·0	32·2	474·1	13,620·1	12,845·9	9,783·6	-	-	-
CA/RA-5	Fall off bike vs cardiac arrest	70s, M	3T	2	NA	220·6	9,990·2	-	0·4	258·2	563·0	83·0	50·0
CA/RA-6	Overdose - heroin	40s, M	3T	3	34·7	80·9	-	4,357·6	2,615·2	-	1,180·0	-	-
CA/RA-7	Found down - SDH and cardiac arrest	60s, F	3T	6	471·3	46,611·1	-	>20,000	>20,000	-	-	-	-
FD-1	Found down - spont IPH	60s, M	5T	4	2,301·2	-	-	437·6	-	-	-	-	-
FD-2	Found down - spont IPH	60s, F	3	6	22,434·9	>50,000	41,925·7	976·7	649·8	775·6	2,180·0	583·0	237·0
FD-3	Found down - spont IPH	50s, M	3	4	42,863·3	24,959·7	26,684·4	1,866·0	386·3	303·6	920·0	622·0	327·0
FD-4	Found down - spont IPH	80s, F	4	4	>50,000	-	-	986·5	-	-	1,020·0	-	-
FD-5	Found down - spont IPH	50s, F	3	3	>50,000	-	-	650·7	-	-	177·0	-	-
FD-6	Found down - spont IPH	50s, M	3	2	18,202·3	-	21,738·1	2,280·1	-	464·9	-	-	-

FD-7	Spontaneous IPH	40s, M	3	2	2,934·1	-	-	38·1	-	-	183·0	-	-
FD-8	Spontaneous IPH	50s, M	13	2	-	5,692·9	3,177·7	-	183·0	175·7	-	-	-
FD-9	Found down	70s, M	5	4	13,671·4	17,459·0	38,300·4	9,113·7	2,863·4	2,225·8	5·0	109·0	90·0
FD-10	Unwitnessed fall	80s, F	3	3	32,136·0	-	>50,000	10,585·1	-	1,939·2	100·0	-	61·0
DAI-1	MVC roll over polytrauma	20s, M	3T	2	48,064·2	11,961·1	33,018·7	2,830·4	435·8	1,245·8	1,060·0	1,400·0	1,030·0
DAI-2	MVC	60s, M	3	3	13,284·3	-	>50,000	7,050·0	-	3,304·1	134·0	-	112·0

Table 2 footnote: Cardiac or respiratory arrest (CA/RA), Found down (FD), Diffuse axonal injury (DAI), and multiple vehicle crash (MVC), Subdural hematoma (SDH), Intraparenchymal Hemorrhage (IPH).

617 **Table 3: Characterization of brain death biomarkers**

Biomarker		Brain Death	CT (+) TBI	CT (-) TBI	Non-Trauma	Controls
GFAP	samples (n)	40	46	49	27	41
	mean, stdev	18,248·3, 19,254·6	2,871·7, - 4,992·5	134·8, 263·7	2,489·5, 6,104·3	13·5, 14·4
	range	15·4 - 50,000	33·2 - 22,178·8	4·7, 1,426·1	3·3 - 27,985	0·6 - 84·5
	t test p value vs brain death	-	0·0000133	0·0000006	0·0000135	0·0000005
UHC-L1	samples (n)	40	46	49	27	41
	mean, stdev	4,108·9, 5,287·1	637·9, 685·8	381·2, 639·6	433·0, 718·2	90·6, 70·9
	range	0·4 - 20,000	4·2 - 2918·5	56 - 4,347·2	45·4 - 3,125·3	0 - 370·5
	t test p value vs brain death	-	0·0001830	0·0000709	0·0000910	0·0000230
S100B	samples (n)	28	30	24	17	38
	mean, stdev	480·6 - 548·6	403·6, 883·0	551·5, 1,316·6	275·2, 468·4	74·3, 42·1
	range	5 - 2,180	16 - 4,280	25 - 6450	23 - 1,840	17 -207
	t test p value vs brain death	-	0·6940469	0·8071675	0·2060105	0·0005538

631 **Table 4 – SVM prediction accuracy from two serum biomarkers (GFAP and UCH-L1) and inclusion of**
632 **multimodal prediction with Blast-CT output.**

Comparison Groups n = 203 samples	GFAP, UCH-L1		GFAP, UCH-L1, Blast-CT	
	AUC	AP	AUC	AP
BD vs. CTL, NT, CTn, CTp	0·95	0·85	0·95	0·86
BD vs. NT, CTn, CTp	0·94	0·85	0·95	0·88
BD vs. NT, CTp	0·91	0·88	0·93	0·90
CA vs. FD, DAI	0·96	0·96	0·99	0·98

Table 4 footnotes: Support vector matrix (SVM), Control (CTL), Non trauma (NT), Computed tomography positive
(CTp), Computed tomography negative (CTn), Found down (FD), and diffuse axonal injury (DAI), Area under the
receiver operator curve (AUC), Average Precision (AP). The right columns of the table includes automated CT
analysis using Blast-CT along with SVM serum biomarker determination of prediction accuracy.

Table 5 – SVM prediction accuracy from three serum biomarkers (GFAP, UCH-L1, and S100B) and
inclusion of multimodal prediction with Blast-CT output.

Comparison Groups n = 137 samples	GFAP, UCH-L1, S100b		GFAP, UCH-L1, S100b, Blast-CT	
	AUC	AP	AUC	AP
BD vs. CTL, NT, CTn, CTp	0·98	0·92	0·96	0·89
BD vs. NT, CTn, CTp	0·96	0·91	0·94	0·89
BD vs. NT, CTp	0·93	0·91	0·93	0·90
CA vs. FD, DAI	0·98	0·97	0·98	0·97

643 Table 5 footnotes: Support vector matrix (SVM), Control (CTL), Non trauma (NT), Computed tomography positive
644 (CTp), Computed tomography negative (CTn), Found down (FD), and diffuse axonal injury (DAI), Area under the
645 receiver operator curve (AUC), Average Precision (AP). The right column of the table includes automated CT
646 analysis using Blast-CT along with SVM serum biomarker determination of prediction accuracy.

A

CTL
NT
CTn
CTp
BD

Log [GFAP] (pg/mL)

B

CTL
NT
CTn
CTp
BD

Log [UCH-L1] (pg/mL)

C

CTL
NT
CTn
CTp
BD

Log [S100B] (pg/mL)